Editor

FRANCISCO  M GONZALEZ OTERO
fco_gonzalez
[+info]

Directorio Médico

address_bookVisite nuestro Directorio Médico, la más completa base de datos de especialistas iberoamericanos en Dermatología Pediátrica
ir al Directorio Médico

Escríbanos

mailComunicarse con nosotros, le responderemos tan pronto sea posible, leemos todos los correos recibidos. Haga clic aquí para ir a nuestro formulario de contacto
Página de Inicio arrow Artículos Científicos arrow Retrospective Analysis of 32 Pediatric Patients with Anticonvulsant Hypersensitivity Syndrome (ACHSS)
Retrospective Analysis of 32 Pediatric Patients with Anticonvulsant Hypersensitivity Syndrome (ACHSS) Imprimir E-Mail
Retrospective Analysis of 32 Pediatric Patients with Anticonvulsant Hypersensitivity Syndrome (ACHSS)
Brandon D. Newell, M.D.*, Maryam Moinfar, M.D.†, Anthony J. Mancini, M.D.†, and Amy Jo Nopper, M.D.*
Pediatric Dermatology Volume 26 Issue 5, Pages 536 - 546


ABSTRACT
 Abstract: 
Objectıve: To review 32 pediatric patients with anticonvulsant hypersensitivity syndrome.
Design: Retrospectively, data and photographs were collected on 32 patients who had been diagnosed with anticonvulsant hypersensitivity syndrome.
Setting: The sections of dermatology at Children's Memorial Hospital in Chicago, Illinois, and Children's Mercy Hospitals and Clinics in Kansas City, Missouri.
Main Outcome Measures: Presentation, implicated medications, laboratory evaluations, complications, treatment and outcome.
Results: The mean age of all patients with anticonvulsant hypersensitivity syndrome (ACHSS) was 8.9 years. The mean duration of anticonvulsant therapy before onset of symptoms was 3 weeks. Phenytoin, carbamazepine, and phenobarbital were the most commonly implicated medications. Lamotrigine, oxcarbamazepine, and primidone were implicated in some of our patients. Fever and rash were seen in all patients, while lymphadenopathy was found in 84.4% of patients. Hematologic abnormalities were seen in 93.8% and hepatic involvement was seen in 90.4% of cases, representing the two most commonly involved systems. Atypical lymphocytosis and eosinophilia was seen in 72% and 56% of patients, respectively. Renal and pulmonary involvement were each seen in 15.6% of cases. Systemic steroids were used in 59.4% of ACHSS patients; 16% of patients received intravenous immunoglobulin. No deaths were reported in our group of pediatric patients.
Conclusions: The ACHSS is a distinct clinical entity which may occur in pediatric patients treated with anticonvulsants, and may have potentially life-threatening consequences. Involvement of multiple organ systems, including the hematologic, hepatic, renal, and pulmonary systems was common. Treatment varied widely, but ranged from supportive care to systemic corticosteroids.
 
< Anterior   Siguiente >
[Volver]

Conferencias Científicas

Traemos a todos los especialistas, un repositorio de conferencias y charlas sobre temas de interés médico y formación de nuevas generaciones especialistas. Invitamos a visitar nuestra galería de Conferencias .